dorzagliatin   Click here for help

GtoPdb Ligand ID: 12124

Synonyms: HMS-5552 | HMS5552 | RO-5305552 | RO5305552 | Sinogliatin
Approved drug
dorzagliatin is an approved drug (China (2022))
Compound class: Synthetic organic
Comment: Dorzagliatin (HMS5552) is an allosteric glucokinase (GCK) activator [3,5], that targets both pancreatic and hepatic GCK, and is a 'full' activator that increases GCK's maximum velocity (Vmax) [7]. GCK activators are being developed as novel drugs for the treatment of type 2 diabetes mellitus (T2DM) [1-2,4].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 116.92
Molecular weight 462.17
XLogP 2.23
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC[C@@H](Cn1ccc(n1)NC(=O)[C@@H](N1CC(=CC1=O)Oc1ccccc1Cl)CC(C)C)O
Isomeric SMILES CC(C)C[C@@H](C(=O)Nc1nn(cc1)C[C@H](CO)O)N1CC(=CC1=O)Oc1ccccc1Cl
InChI InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
InChI Key HMUMWSORCUWQJO-QAPCUYQASA-N
No information available.
Summary of Clinical Use Click here for help
Dorzagliatin (HMS5552) was advanced to phase 3 clinical trial to evaluate its efficacy to improve glycaemic control in diabetes. First approval was granted in China in September 2022, for the treatment of T1DM and T2DM, and diabetic kidney disease (DKD).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04531631 Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2 Interventional Chinese University of Hong Kong
NCT05098470 Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity Phase 3 Interventional University of Virginia
NCT03173391 Long-term Efficacy and Safety of HMS5552 in T2DM Subjects Phase 3 Interventional Hua Medicine Limited
NCT03141073 Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects Phase 3 Interventional Hua Medicine Limited 6